, Volume 8, Issue 4, pp 258–266 | Cite as

Extensive personal experience. Validation of prolactin levels in menstrual disorders and in prolactinomas

  • Menelaos L. BatrinosEmail author
Personal experience


Galactorrhoea Hyperprolactinaemia Menstrual disorders Prolactinomas 


  1. 1.
    Molitch ME, 1995 Prolactinoma. In Melmed S (ed) The pituitary. Blackwell Science Inc; pp, 443–477.Google Scholar
  2. 2.
    Chahal J, Schlechte J, 2008 Hyperprolactineamia. Pituitary 11: 141–146.CrossRefGoogle Scholar
  3. 3.
    Mancini T, Casanueva FF, Giustina A, 2008 Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin N Am 37: 67–99.CrossRefGoogle Scholar
  4. 4.
    Schlechte JA, 2003 Clinical practice. Prolactinoma. N Engl J Med 349: 2035–2041.CrossRefGoogle Scholar
  5. 5.
    Batrinos ML, Panitsa-Faflia Ch, Tsiganou E, Liapi Ch, 1992 Incidence and Characteristics of Microprolactino-mas (3–5mm) in 4199 Women Assayed for Prolactin. Horm Metab Res 24: 384–391.CrossRefGoogle Scholar
  6. 6.
    Batrinos M, Panitsa-Faflia Ch, Tsiganou E, Pitoulis G, Liapi Ch, 1994 Contribution to the problem of Hyper-prolactinaemia: Experience with 4.199 Prolactin assays and 117 prolactinomas. Int J Fertil 39: 120–127.Google Scholar
  7. 7.
    Hauache OM, Rocha AJ, Maia Jr, Maciel RMB, Vieira JGH, 2002 Screening for macroprolactinaemia and pituitary imaging studies. Clin Endocrinol 57: 327–331.CrossRefGoogle Scholar
  8. 8.
    Vallette-Kasic S, Morange-Ramos I, Selim A, et al, 2002 Macroprolactinemia revisited: A study on 106 patients. J Clin Endocrinol Metab 87: 581–588.CrossRefGoogle Scholar
  9. 9.
    Brucero N, Zecur HA, 2001 Polycystic ovary syndrome and hyperprolactinemia. Obstet Gynecol Clin North Am 28: 77–84.CrossRefGoogle Scholar
  10. 10.
    Filho RB, Domingues L, Naves L, Ferraz E, Alves A, Casulari LA, 2007 Polycystic ovary syndrome and hyper-prolactinemia are distinct entities. Gynecol Endocrinol 23: 267–272.CrossRefGoogle Scholar
  11. 11.
    Cortet-Rudelli C, Sapin R, Bonneville JF, Brue T, 2007 Etiological diagnosis of hyperprolactinemia. Ann Endocrinol (Paris) 68: 98–105.CrossRefGoogle Scholar
  12. 12.
    Davis JR, Farrell WE, Clayton RN, 2001 Pituitary tumours. Reproduction 121: 363–371.CrossRefGoogle Scholar
  13. 13.
    Ciccarelli A, Daly AF, Beckers A, 2005 The epidemiology of prolactinomas. Pituitary 8: 3–6.CrossRefGoogle Scholar
  14. 14.
    Daly AF, Rixhon M, Adam C, Dempegioti A, et al, 2006 High prevalence of pituitary adenomas: a cross-sectional study in the presence of Liege Belgium. J Clin Endocrinol Metab 91: 4769–4775.CrossRefGoogle Scholar
  15. 15.
    Bayrak A, Saadat P, Mor E, Chong L, Paulson RJ, Sokol RZ, 2005 Pituitary imaging is indicated for the evaluation of hyperprolactinemia. Fertile Steril 84: 181–185.CrossRefGoogle Scholar
  16. 16.
    Wolpert SM, Molitch ME, Goldman JA, Wood JB, 1984 Size, shape, and appearance of the normal female pituitary gland. Am J Roentgenol 143: 377–381.CrossRefGoogle Scholar
  17. 17.
    Hall WA, Luciano MG, Doppman JL, Patronas J, Old-field EH, 1994 Pituitary magnetic resonance imaging in normal human volunteers: Occult adenomas in the general population. Ann Int Med 120: 817–820.CrossRefGoogle Scholar
  18. 18.
    Costello RT, 1936 Subclinical adenoma of the pituitary gland. Am J Pathology 12: 205–216.Google Scholar
  19. 19.
    McCormick WF, Halmi NS, 1971 Absence of chromophobe adenomas from a large series of pituitary tumors. Arch Pathol 92: 231–238.PubMedGoogle Scholar
  20. 20.
    Parent AD, Bebin J, Smith RR, 1981 Incidental pituitary adenomas. J Neurosurg 54: 228–231.CrossRefGoogle Scholar
  21. 21.
    Muhr C, Bergstrom K, Grimelius L, Larsson SG, 1981 Parallel study of the sella turcica and the histopathology of the pituitary gland in 205 autopsy specimens. Neuroradiology 21: 55–65.CrossRefGoogle Scholar
  22. 22.
    El-Hamid MW, Joplin GF, Lewis PD, 1988 Incidentally found small pituitary adenomas may have no effect on fertility. Acta Endocrinol 117: 361–364.CrossRefGoogle Scholar
  23. 23.
    Kovacs K, Ryan N, Horvath E, Singer W, Erzin C, 1980 Pituitary adenomas in old age. J Gerontol 35: 16–22.CrossRefGoogle Scholar
  24. 24.
    Burrow GN, Wortzman G, Rewcastle NB, Holgate RC, Kovacs K, 1981 Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med 304: 156–158.CrossRefGoogle Scholar
  25. 25.
    Von Schvenziger G, Warzok IZ, 1981 Hyperplasien und adenoma der hypophyse in uuselectierten sections gut. Zbl Allg Pathol u Pathol Ahat 126: 495–498.Google Scholar
  26. 26.
    Teramoto A, Hirakava K, Sann N, Osamura Y, 1994 Incidental pituitary tumors in 100 unselected autopsy specimens. Radiology 193: 161–164.CrossRefGoogle Scholar
  27. 27.
    Buurman H, Saeger W, 2006 Subclinical adenomas in post-mortem pituitaries: classification and correlations to clinical data. Eur J Endocrinol 154: 753–758.CrossRefGoogle Scholar
  28. 28.
    Schlechte JA, 2007 Long-term management of prolactinomas. J Clin Endrocrinol Metab 92: 2861–2865.CrossRefGoogle Scholar
  29. 29.
    Gillam Mp, Molitch ME, Lombardi G, Colao A 2006 Advances in the treatment of prolactinomas. Endocr Rev 27: 485–534.CrossRefGoogle Scholar
  30. 30.
    Casanueva FF, Molitch ME, Schlechte JA, et al, 2006 Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol 65: 265–273.CrossRefGoogle Scholar
  31. 31.
    Weiss MH, Teal J, Gott P, et al, 1983 Natural history of microprolactinomas: six years follow-up. Neurosurgery 12: 180–183.CrossRefGoogle Scholar
  32. 32.
    Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A, 1989 The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68: 412–418.CrossRefGoogle Scholar
  33. 33.
    Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A, 1989 The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endcrinol and Metab 68: 412–418.CrossRefGoogle Scholar
  34. 34.
    Passos VQ, Souza JJ, Musolino NR, Bronstein MD, 2002 Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 87: 3578–3582.CrossRefGoogle Scholar
  35. 35.
    Colao A, Di Sarno A, Coppabianca P, De Somma C, Pivonello R, Lombardi G, 2003 Withdrawal of long-term carbegoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349: 2023–2033.CrossRefGoogle Scholar
  36. 36.
    Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G, 2003 Withdrawal of long-term cabergoline therapy for tumoural and nontumoural hyperprolactinaemia. N Engl J Med 349: 2023–2033.CrossRefGoogle Scholar
  37. 37.
    Biswas M, Smith J, Jadon D, et al, 2005 Long-term remission following withdrawal of dopamine agonist therapy in subjects with mircroprolactinemia. Clin Endocrinol (Oxf) 63: 26–31.CrossRefGoogle Scholar
  38. 38.
    Colao A, Di Sarno A, Guerra E, et al, 2007 Predictors of remission of hyperprolactinemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol (Oxf) 67: 426–433.CrossRefGoogle Scholar
  39. 39.
    Molitch ME, 2003 Dopamine resistance of prolactinomas. Pituitary 6: 19–27.CrossRefGoogle Scholar
  40. 40.
    Kars M, Pereira AM, Romijin JA, 2008 Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol 159: 363–367.CrossRefGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2009

Authors and Affiliations

  1. 1.Athens University Medical SchoolAthensGreece

Personalised recommendations